HOUSE_OVERSIGHT_028418.jpg

pitch its story to Wall Street. It settled on Mr. Hugin, a managing director at J.P.
Morgan.","type":"text"}, {"bannerType":"any", "identifier":"anf-banner_advertisement-
5", "layout": "ComponentLayout-
4","role": "banner advertisement", "type": "banner advertisement"},{"additions":[{"URL":"h tps://bobhugin.com/about/","range":{"length":19,"start":176},"type":"link"},{"URL":"ht
tps://www.sec.gov/Archives/edgar/data/816284/000100515000000449/0001005150-00-
000449.txt","range":{"length":21,"start": 223},"type":"link"}],"identifier":" anf-body-
27","inlineTextStyles":[{"range":{"length":461,"start":0},"textStyle":"
anf-ts-
1"},{"range":{"length":461,"start":0},"textStyle":"anf-ts-1"}],"layout": "default-
body", "role":"body","text": "At the time, the company’s financial situation was
perilous. Celgene had 200 employees and was getting by on less than six weeks of cash
when Mr. Hugin joined, according to his campaign biography. A year later, the company
warned investors that, “during the next several years, we will be very dependent on
the commercial success of Thalomid,†while also acknowledging that the market for the
only disease for which the drug was approved was “relatively
small.â€","type":"text"},{"identifier":" anf-heading4-
2", "layout": "heading4","role": "heading4","text":"Seeking a windfall by exploiting drug
safety rules","type":"text"}, {"identifier":" anf-body-
28","inlineTextStyles":[{"range":{"length":387,"start":0},"textStyle":" anf-ts-
1"},{"range":{"length":387,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-
body", "role":"body","text":"Drug companies are forbidden from promoting a drug for any
unapproved uses, but doctors have broad discretion to prescribe a product for a range
of diseases. Celgene appeared to exploit this distinction almost as soon as Thalomid
arrived on the market, according to company filings, public statements and internal
documents included in the whistle-blower lawsuit Celgene settled in
2017.", "type":"text"},{"identifier":" anf-body-
29","inlineTextStyles":[{"range":{"length":257,"start":0},"textStyle":"_anf-ts-
1"},{"range":{"length":257,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-
body", "role":"body","text":"The company hired a team of 60 sales representatives, many
of whom had experience in oncology, according to financial filings, and just months
after Thalomid arrived on the market, Celgene announced that it would pursue F.D.A.
approval for multiple myeloma.", "type":"text"}, {"components": [{"caption": "Mr. Hugin has
defended his role as a top executive at Celgene, saying that he helped lead a company
that developed life-saving medicines. Rick Loomis for The New York
Times", "captionComponent":{"text":"Mr. Hugin has defended his role as a top executive
at Celgene, saying that he helped lead a company that developed life-saving medicines.
Rick Loomis for The New York
Times"},"identifier":"100000006098033 5ba8b804122ca", "imageIdentifier":"c275d4ffa64cd56
96e6a2645c43f84a0","layout":"fullbleed-
image", "role":"photo", "type": "scalable image"},{"identifier":" anf-caption-
3","inlineTextStyles":[{"range":{"length":35,"start":138},"textstyle":"photo-
credit"}],"layout": "default-caption", "role":"caption", "text":"Mr. Hugin has defended
his role as a top executive at Celgene, saying that he helped lead a company that
developed life-saving medicines. Rick Loomis for The New York Times
","type":"text"}],"identifier":"anf-container-2","layout":"image-
container","role":"container","type":"container"}, {"additions":[{"URL":"http://wayback.
archive-
it.org/7993/20170112071439/http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat
oryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPh
armaceuticalCompanies/UCM167840.pdf", "range":{"length":47,"start":100},"type":"link"},{
"URL":"https://www.washingtonpost.com/archive/politics/2000/05/05/fda-moves-to-curb-
ads-for-thalidomide/dd6ce44a-711b-424c-a9a0-
ae67168f170c/?utm_term=.f0af824af352","range":{"length":16,"start":246},"type":"link"}]
"identifier":" anf-body-
30","inlineTextStyles":[{"range":{"length":319,"start":0},"textStyle":" anf-ts-
1"},{"range":{"length":319,"start":0},"textStyle":" anf-ts-1"}],"layout": "default-
body", "role":"body","text":"The F.D.A. reprimanded Celgene multiple times in those
early years, telling the company that it had not adequately warned about
thalidomide’s risks in its announcement about multiple myeloma, and calling a meeting
in December 1998 to warn of its “strong concern†that Celgene was marketing Thalomid
for unapproved uses.","type":"text"}, {"bannerType":"any","identifier":"anf-
banner_advertisement-6","layout":"ComponentLayout-
4","role":"banner_advertisement","type":"banner_advertisement"},{"additions":[{"URL":"h
ttp://wayback.archive-
it.org/7993/20170112070734/http://www.fda.gov/downloads. gov/downloads/Drugs/GuidanceComplianceRegulat
oryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPh
armaceuticalCompanies/UCM165843.pdf", "range":{"length":41,"start":9},"type":"link"}],"i
HOUSE_OVERSIGHT_028418